7 results on '"Avik Shome"'
Search Results
2. Comprehensive Grading System for Experimental Autoimmune Uveitis in Mice
- Author
-
Avik Shome, Odunayo O. Mugisho, Rachael L. Niederer, and Ilva D. Rupenthal
- Subjects
uveitis ,inflammation ,experimental autoimmune uveitis ,fundus imaging ,optical coherence tomography ,Biology (General) ,QH301-705.5 - Abstract
Experimental autoimmune uveitis (EAU) is the most commonly used animal model to study the progression of chronic uveitis and to test various therapies to treat the disease. However, to accurately evaluate the effectiveness of such treatments, a grading system that combines the latest imaging techniques with definitive quantitative grading thresholds is required. This study aimed to develop a comprehensive grading system that objectively evaluates EAU progression in C57BL/6J mice. EAU was induced following immunisation with interphotoreceptor retinoid-binding protein (IRBP) and pertussis toxin. Weekly fundus and optical coherence tomography (OCT) images were acquired over 12 weeks using a Micron IV imaging system. Each mouse was graded (between 0 to 4) based on changes seen on both the fundus (optic disc, retinal blood vessels and retinal tissue) and OCT (vitreous and retinal layers) images. A total EAU response (with a maximum score of 48) was calculated for each mouse based on the sum of the individual scores each week. Analysis of the clinical scores depicted a gradual increase in inflammatory signs including optic disc and vascular swelling, leukocyte infiltration in the vitreous, lesions in the retina and formation of granulomas and hyper-reflective foci in the retinal layers in EAU mice, with most signs reaching a plateau towards the end of the study period. Development of these signs into sight-threatening complications such as optic disc atrophy, structural damage to the retina and subretinal oedema were noted in 80–90% of mice suggesting consistent disease induction. Overall, a comprehensive and objective grading system encompassing all pathologies occurring in EAU mice was developed to enhance the preclinical evaluation of novel uveitis treatments.
- Published
- 2023
- Full Text
- View/download PDF
3. Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
- Author
-
Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, and Michael P. Hay
- Subjects
chemoradiotherapy ,DNA damage ,electron affinity ,hypoxia ,nitroimidazole ,prodrugs ,Organic chemistry ,QD241-441 - Abstract
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiotherapy herald new opportunities for classical oxygen-mimetic radiosensitisers. Only nimorazole is used clinically as a radiosensitiser, and there is a dearth of new radiosensitisers in development. In this report, we augment previous work to present new nitroimidazole alkylsulfonamides and we document their cytotoxicity and ability to radiosensitise anoxic tumour cells in vitro. We compare radiosensitisation with etanidazole and earlier nitroimidazole sulfonamide analogues and we identify 2-nitroimidazole and 5-nitroimidazole analogues with marked tumour radiosensitisation in ex vivo assays of surviving clonogens and with in vivo tumour growth inhibition.
- Published
- 2023
- Full Text
- View/download PDF
4. Desacetyl-α-melanocyte stimulating hormone and α-melanocyte stimulating hormone are required to regulate energy balance
- Author
-
Kathleen G. Mountjoy, Alexandre Caron, Kristina Hubbard, Avik Shome, Angus C. Grey, Bo Sun, Sarah Bould, Martin Middleditch, Beau Pontré, Ailsa McGregor, Paul W.R. Harris, Renata Kowalczyk, Margaret A. Brimble, Rikus Botha, Karen M.L. Tan, Sarah J. Piper, Christina Buchanan, Syann Lee, Anthony P. Coll, and Joel K. Elmquist
- Subjects
Internal medicine ,RC31-1245 - Abstract
Objective: Regulation of energy balance depends on pro-opiomelanocortin (POMC)-derived peptides and melanocortin-4 receptor (MC4R). Alpha-melanocyte stimulating hormone (α-MSH) is the predicted natural POMC-derived peptide that regulates energy balance. Desacetyl-α-MSH, the precursor for α-MSH, is present in brain and blood. Desacetyl-α-MSH is considered to be unimportant for regulating energy balance despite being more potent (compared with α-MSH) at activating the appetite-regulating MC4R in vitro. Thus, the physiological role for desacetyl-α-MSH is still unclear. Methods: We created a novel mouse model to determine whether desacetyl-α-MSH plays a role in regulating energy balance. We engineered a knock in targeted QKQR mutation in the POMC protein cleavage site that blocks the production of both desacetyl-α-MSH and α-MSH from adrenocorticotropin (ACTH1-39). Results: The mutant ACTH1-39 (ACTHQKQR) functions similar to native ACTH1-39 (ACTHKKRR) at the melanocortin 2 receptor (MC2R) in vivo and MC4R in vitro. Male and female homozygous mutant ACTH1-39 (Pomctm1/tm1) mice develop the characteristic melanocortin obesity phenotype. Replacement of either desacetyl-α-MSH or α-MSH over 14 days into Pomctm1/tm1 mouse brain significantly reverses excess body weight and fat mass gained compared to wild type (WT) (Pomcwt/wt) mice. Here, we identify both desacetyl-α-MSH and α-MSH peptides as regulators of energy balance and highlight a previously unappreciated physiological role for desacetyl-α-MSH. Conclusions: Based on these data we propose that there is potential to exploit the naturally occurring POMC-derived peptides to treat obesity but this relies on first understanding the specific function(s) for desacetyl-α-MSH and α-MSH. Keywords: POMC, Obesity, Desacetyl-α-MSH, α-MSH, Obese mouse model
- Published
- 2018
- Full Text
- View/download PDF
5. Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
- Author
-
Hay, Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, and Michael P.
- Subjects
chemoradiotherapy ,DNA damage ,electron affinity ,hypoxia ,nitroimidazole ,prodrugs ,radiosensitisers ,radiotherapy ,sulfonamide ,tumour microenvironment - Abstract
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiotherapy herald new opportunities for classical oxygen-mimetic radiosensitisers. Only nimorazole is used clinically as a radiosensitiser, and there is a dearth of new radiosensitisers in development. In this report, we augment previous work to present new nitroimidazole alkylsulfonamides and we document their cytotoxicity and ability to radiosensitise anoxic tumour cells in vitro. We compare radiosensitisation with etanidazole and earlier nitroimidazole sulfonamide analogues and we identify 2-nitroimidazole and 5-nitroimidazole analogues with marked tumour radiosensitisation in ex vivo assays of surviving clonogens and with in vivo tumour growth inhibition.
- Published
- 2023
- Full Text
- View/download PDF
6. Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy
- Author
-
Heather Lyon, Ilva D. Rupenthal, Colin R. Green, Odunayo O Mugisho, and Avik Shome
- Subjects
0301 basic medicine ,hemichannels ,tonabersat ,Inflammasomes ,medicine.medical_treatment ,Retinal Pigment Epithelium ,Pharmacology ,lcsh:Chemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Medicine ,lcsh:QH301-705.5 ,Spectroscopy ,Caspase 1 ,Inflammasome ,General Medicine ,Diabetic retinopathy ,Computer Science Applications ,diabetic retinopathy ,Cytokine ,Benzamides ,Cytokines ,Tumor necrosis factor alpha ,Inflammation Mediators ,medicine.symptom ,Ion Channel Gating ,medicine.drug ,Inflammation ,Article ,Catalysis ,Connexon ,Cell Line ,Proinflammatory cytokine ,Inorganic Chemistry ,03 medical and health sciences ,inflammasome ,NLR Family, Pyrin Domain-Containing 3 Protein ,Humans ,Benzopyrans ,Physical and Theoretical Chemistry ,Molecular Biology ,business.industry ,Organic Chemistry ,Epithelial Cells ,Retinal ,medicine.disease ,connexin43 ,Glucose ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,chemistry ,inflammation ,Connexin 43 ,030221 ophthalmology & optometry ,business - Abstract
This study was undertaken to evaluate the connexin hemichannel blocker tonabersat for the inhibition of inflammasome activation and use as a potential treatment for diabetic retinopathy. Human retinal pigment epithelial cells (ARPE-19) were stimulated with hyperglycemia and the inflammatory cytokines IL-1β and TNFα in order to mimic diabetic retinopathy molecular signs in vitro. Immunohistochemistry was used to evaluate the effect of tonabersat treatment on NLRP3, NLRP1, and cleaved caspase-1 expression and distribution. A Luminex cytokine release assay was performed to determine whether tonabersat affected proinflammatory cytokine release. NLRP1 was not activated in ARPE-19 cells, and IL-18 was not produced under disease conditions. However, NLRP3 and cleaved caspase-1 complex formation increased with hyperglycemia and cytokine challenge but was inhibited by tonabersat treatment. It also prevented the release of proinflammatory cytokines IL-1β, VEGF, and IL-6. Tonabersat therefore has the potential to reduce inflammasome-mediated inflammation in diabetic retinopathy.
- Published
- 2020
- Full Text
- View/download PDF
7. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
- Author
-
Reidar Grénman, John Nemunaitis, Mark Zaidi, William R. Wilson, Courtney R. H. Lynch, Trevor D. McKee, Cho R. Hong, Peter Tsai, Charles P. Hart, Dennis Kee, Purvi M. Kakadia, John M. Chaplin, Tet Woo Lee, Bradly G. Wouters, Stephen M. F. Jamieson, Arthur Liu, Nicholas P. McIvor, Francis W. Hunter, Shadia I. Jalal, Cristin G. Print, Nicholas Knowlton, E. Gabriela Chiorean, Nooriyah Poonawala-Lohani, Way W. Wong, Kevin O. Hicks, Dan Li, Laura Caporiccio, Neil Senzer, Avik Shome, Michael A. Curran, Andrew Macann, Pratha Budhani, Maria Kondratyev, Stefan K. Bohlander, and Sehrish Butt
- Subjects
Adult ,0301 basic medicine ,medicine.medical_treatment ,Cell ,Phases of clinical research ,Antineoplastic Agents ,Inhibitory Concentration 50 ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Line, Tumor ,Exome Sequencing ,Biomarkers, Tumor ,medicine ,Humans ,Prodrugs ,Papillomaviridae ,Response Evaluation Criteria in Solid Tumors ,Aged ,Evofosfamide ,Tumor hypoxia ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Human Papillomavirus Negative ,Chemoradiotherapy ,General Medicine ,Middle Aged ,medicine.disease ,ta3122 ,Xenograft Model Antitumor Assays ,Head and neck squamous-cell carcinoma ,Progression-Free Survival ,Nitrogen mustard ,Radiation therapy ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Drug Resistance, Neoplasm ,Head and Neck Neoplasms ,Nitroimidazoles ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Phosphoramide Mustards ,business ,Research Article - Abstract
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line–derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.